Welcome to our dedicated page for Sintx Technologies SEC filings (Ticker: SINT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to SINTX Technologies, Inc. (NASDAQ: SINT) SEC filings, offering detailed insight into the company’s silicon nitride biomaterials business, capital structure, and governance. Filings are sourced in real time from the SEC’s EDGAR system and organized so investors can quickly locate key documents.
Through SINTX’s annual reports on Form 10‑K and quarterly reports on Form 10‑Q, readers can review narrative business descriptions, risk factors, financial statements, and management’s discussion of its advanced ceramics and medical device operations. These reports also describe the company’s focus on infection‑resistant silicon nitride devices, polymer composites, and antipathogenic fabric technologies, as well as its U.S.‑based manufacturing footprint and patent portfolio.
Current reports on Form 8‑K document material events such as FDA 510(k) submissions and clearances, asset purchase agreements, at‑the‑market offering arrangements, warrant inducement transactions, and other financing activities. For example, recent 8‑K filings describe an ATM Offering Agreement with H.C. Wainwright & Co., an inducement agreement related to warrant exercises, and an asset purchase agreement for foot and ankle implant assets.
The DEF 14A proxy statement provides information on board elections, auditor ratification, executive compensation proposals, and equity incentive plans, along with details about the annual meeting of stockholders. Together, these filings help investors understand SINTX’s governance structure and shareholder matters.
Stock Titan’s platform enhances these documents with AI‑powered summaries that highlight important sections, such as business updates, capital‑raising terms, and key risk disclosures, reducing the time needed to interpret lengthy filings. Users can also review Form 4 and related insider transaction filings to see how directors and officers transact in SINTX common stock over time.
By using this page, investors can efficiently navigate SINTX’s 10‑K, 10‑Q, 8‑K, proxy, and insider filings, while AI‑generated insights point to the sections most relevant to the company’s silicon nitride technology platform and financial condition.
Sintx Technologies director and Chief Investment Officer Kevin Ontiveros reported significant increases in his ownership of the company’s common stock. On 12/05/2025, he made a series of open-market purchases, each for 5,000 shares of common stock, at prices ranging from $3.77 to $4.07 per share. After these purchases, his directly held stake rose to 139,000 shares.
On the same date, he also received an additional 53,867 common shares at a price of $0.00, described as an issuance incident to the vesting of a Restricted Stock Unit Award. Following this vesting, his directly owned common stock position increased further to 192,867 shares, highlighting both active open-market buying and equity compensation-based ownership growth.
SINTX Technologies furnished an 8-K announcing financial results for the quarter ended September 30, 2025. The results were released via a press release furnished as Exhibit 99.1, which also discusses the company’s use of a non-GAAP financial measure.
The information in Item 2.02 and Exhibit 99.1 is furnished, not filed, and is not incorporated by reference except as expressly stated. The Item 2.02 information is also included under Item 7.01 by reference.
SINTX Technologies filed its Q3 2025 10‑Q, reporting total revenue of $208k (down 74% year over year) and a net loss of $3.539M. Gross profit was $93k, with operating expenses of $3.448M driven by R&D $1.264M and G&A $2.102M. Cash and cash equivalents were $6.250M as of September 30, 2025.
The company continued shifting away from low‑margin OEM work toward proprietary silicon nitride medical devices. It received FDA 510(k) clearance in October 2025 for the SiNAPTIC Foot & Ankle Osteotomy Wedge System, with revenue expected to begin in the first half of 2026. Q3 also included an inducement in which holders exercised warrants for ~$3.8M in gross proceeds, creating a $6.7M deemed dividend.
SINTX strengthened liquidity with a $6.41M at‑the‑market facility established in October 2025 and expects ~$950k savings from subleasing the armor facility. Management states no significant uncertainty regarding its ability to continue as a going concern through at least November 12, 2026. Shares outstanding were 3,851,956 as of November 7, 2025.
Sintx Technologies (SINT) insider activity: A company director and Chief Investment Officer reported open‑market purchases on 11/07/2025. The filer bought 5,000 shares at $3.20 and 5,000 shares at $3.18, increasing beneficial ownership to 74,000 shares, held directly.
SINTX Technologies (Nasdaq: SINT) filed a resale registration covering up to 1,741,539 shares of common stock to be offered by selling stockholders. The registered shares consist of 1,649,147 common warrant shares and 92,392 placement agent warrant shares issued in connection with a February 2025 private placement and an inducement letter dated September 8, 2025.
The company is not selling any shares in this prospectus and will not receive proceeds from selling stockholder resales. SINTX would receive up to approximately $8.3 million only if the warrants are exercised for cash; stated exercise prices include $4.79 for the common warrants and $4.3844 and $4.3125 for the placement agent warrants. Any cash received from exercises will be used for working capital and general corporate purposes.
Shares may be sold by the holders at market, fixed, related, or negotiated prices through various methods described in the plan of distribution. Shares outstanding were 3,683,989 as of October 20, 2025; this is a baseline figure, not the amount being registered. The last reported SINT price was $3.25 on October 22, 2025.
SINTX Technologies (SINT) filed a Form 4 reporting an insider purchase. The company’s President and CEO, who also serves as a director, purchased 5,800 shares of common stock on 10/20/2025 at a price of $3.4 per share.
Following this transaction, the reporting person beneficially owns 30,775 shares, held directly. The filing indicates it was submitted by one reporting person.
Sintx Technologies, Inc. filed a prospectus supplement for a securities offering that discloses pro forma tangible book value and recent capital-raising activity. As of June 30, 2025 the company reported a net tangible book value per share of $1.60. Following the issuance of 723,873 shares in a warrant inducement offering that closed on September 8, 2025 for net proceeds of approximately $3.35 million, pro forma net tangible book value per share rose by $0.68 to $2.28. The current offering would further increase pro forma net tangible book value per share by $0.53, producing a pro forma as adjusted value of $2.81 per share and resulting in dilution to new investors of $1.28 per share.
The document contains table-of-contents material and references to incorporated filings and exhibits but does not provide full disclosure of the total shares outstanding immediately after the offering or detailed use-of-proceeds amounts in the excerpt provided.
FAQ
What is the current stock price of Sintx Technologies (SINT)?
What is the market cap of Sintx Technologies (SINT)?
